pSivida (NASDAQ:PSDV) received a $5.00 price target from HC Wainwright in a research report issued on Thursday. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 380.77% from the stock’s current price.

A number of other analysts have also recently weighed in on the company. B. Riley set a $5.00 price target on pSivida and gave the company a “buy” rating in a research note on Friday, December 15th. Northland Securities restated a “buy” rating and issued a $10.00 price target on shares of pSivida in a research note on Monday, December 11th. ValuEngine lowered pSivida from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, Laidlaw began coverage on pSivida in a report on Wednesday, November 8th. They set a “buy” rating and a $5.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. pSivida presently has an average rating of “Buy” and an average price target of $7.57.

Shares of pSivida (NASDAQ:PSDV) opened at $1.04 on Thursday. pSivida has a 52 week low of $0.93 and a 52 week high of $2.45.

pSivida (NASDAQ:PSDV) last posted its quarterly earnings results on Wednesday, February 7th. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. pSivida had a negative return on equity of 198.23% and a negative net margin of 882.37%. The company had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.48 million. equities analysts expect that pSivida will post -0.59 EPS for the current fiscal year.

An institutional investor recently bought a new position in pSivida stock. OxFORD Asset Management LLP acquired a new position in shares of pSivida Corp. (NASDAQ:PSDV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned about 0.18% of pSivida as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 9.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at

pSivida Company Profile

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Analyst Recommendations for pSivida (NASDAQ:PSDV)

Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with's FREE daily email newsletter.